Demonstration of active osteoarthropathy at In-111 Zevalin scan in a patient with non-Hodgkin’s lymphoma

TL;DRAbstract

1067 Learning Objectives 1. To review the normal and abnormal pattern of In-111 Zevalin biodistribution, particularly caused by active osteoarthropathy (AO). 2. To discuss possible consequences of AO on the 90Y-Zevalin treatment in patients with CD20 receptor-positive non-Hodgkin’s lymphoma(NHL). 90Y-Zevalin is an effective treatment for CD20 receptor-positive NHL. It has been approved for patients who achieve a partial or complete response to first-line chemotherapy, or have relapsed or refractory, low-grade or follicular B-cell NHL. We present a 70-year-old woman with stage IIIa follicular B-cell lymphoma who completed chemotherapy with R-CHOP in 4/2008, and achieved complete remission initially. However, she showed evidence of early relapse in 9/2008 seen as FDG avid lymph nodes in the mediastinum, abdomen and pelvis. Subsequent pleurectomy and mediastinal biopsy confirmed B-cell lymphoma. Bone marrow biopsy was negative. She was then treated with R-CMOPP. There was partial treatmen

Chat with Paper

AI Agents for this Paper